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Introduction {#sec005}
============

Over the past decades, increasing efforts have been made to identify best practices for controlled ovarian stimulation (COS) and embryo culture for In Vitro Fertilization (IVF) treatment \[[@pone.0220450.ref001]\]. In contrast, the luteal phase subsequent to the COS and oocyte retrieval have received less interest for a long time \[[@pone.0220450.ref002]\]. By modifying gene expression, progesterone guides the endometrial secretory transformation and therefore plays a fundamental role in implantation and early embryologic development \[[@pone.0220450.ref003],[@pone.0220450.ref004]\]. After COS, the endogenous secretion of progesterone by the granulosa of the corpus luteum is insufficient \[[@pone.0220450.ref005]\]. The luteolytic effect of the GnRH analogs or GnRH antagonists used for the COS, inhibition of the hypothalamic-pituitary axis by the supra-physiological secretion of steroids, and aspiration of the granulosa cells during oocyte retrieval are the main hypotheses for this inadequate secretion \[[@pone.0220450.ref006]\]. Luteal phase support (LPS) compensates for this deficiency by supplementing with either progesterone or an hCG or GnRH agonist \[[@pone.0220450.ref007]\].

In recent years, clinical investigators have shown a renewed interest in the luteal phase subsequent to ART treatments. Evidence is accumulating regarding the existence of an optimal range of P~4~ levels on the day of embryo transfer (ET) in frozen embryo transfer cycles with hormone replacement therapy \[[@pone.0220450.ref008]--[@pone.0220450.ref010]\]. In 2018, Thomsen et al. published the results of a large prospective cohort study of 602 women who underwent IVF treatment and had serum P~4~ levels measured on the day of ET \[[@pone.0220450.ref011]\]. The authors determined that very low P~4~ levels (\< 60 nmol/l) on the day of fresh ET (Day 2--3 after oocyte pick-up (OPU)) were associated with decreased chance of success of the IVF treatment. This result allows us to consider a possible value of early luteal P~4~ monitoring and luteal rescue by increasing the P~4~ supplementation. Thomsen et al. also reported that high P~4~ levels (\> 400 nmol/l) were associated with a decreased chance of live birth after IVF treatment. If confirmed by other studies, these thresholds could encourage the cancellation of ET for women with high early luteal P~4~ levels.

However, concerns have been raised regarding the statistical analysis of the aforementioned study \[[@pone.0220450.ref012]\], and further studies are needed to assess the reproducibility of the suggested thresholds before they can be used in common practice, in particular with different COS and LPS protocols.

A recent large phase III RCT demonstrated the noninferiority of oral dydrogesterone compared with micronized vaginal progesterone for LPS in terms of pregnancy rates and tolerability \[[@pone.0220450.ref013]\]. Thus, dydrogesterone was recently approved for LPS in IVF \[[@pone.0220450.ref014]\]. Furthermore, given the assumed preference for the oral route over vaginal route, dydrogesterone is presumed to become the new standard for LPS in IVF treatment according to some authors \[[@pone.0220450.ref015]\]. The early luteal phase P~4~ levels have never been studied in the context of the use of dydrogesterone for LPS \[[@pone.0220450.ref016]\].

Throughout this retrospective data analysis, we aimed to determine if early luteal P~4~ levels (on the day of fresh ET) could allow us to predict the success of IVF on an unselected population treated with oral dydrogesterone for LPS.

Materials and methods {#sec006}
=====================

Study design {#sec007}
------------

We conducted a monocentric retrospective cohort study. Data were retrospectively and anonymously collected. Before the study began, it was approved by the ethics committee of Aix Marseille University. All patients were informed of the anonymous and retrospective use of their data and could refuse to participate by simple notification.

Study population {#sec008}
----------------

We enrolled couples who underwent IVF or ICSI treatments in our ART unit between July 2017 and June 2018 and who had early luteal phase serum P~4~ levels measured on the day of fresh ET (Day 2--3 after OPU). Women were eligible for inclusion regardless of the reason for the infertility or the number of previous unsuccessful IVF or ICSI cycles.

Ovarian stimulation protocols {#sec009}
-----------------------------

The choices of COS protocols and gonadotrophin doses were made in accordance with the standards of our ART unit based on age, BMI, ovarian reserve, outcomes of previous IVF or ICSI cycles, and other comorbidities such as endometriosis or polycystic ovary syndrome (PCOS). GnRH antagonist protocols were generally used as the first choice, especially for patients with an expected low ovarian response and for women with PCOS; in contrast, GnRH long agonist protocols were used for patients with endometriosis or as a second choice for patients with an inadequate response to the previous GnRH antagonist protocol. Short GnRH agonist protocols were used for low responders who had already experienced several failures after previous stimulations.

Patients who were treated in a long GnRH-agonist protocol were downregulated using a unique IM injection of 3 mg triptorelin (Decapeptyl, Ipsen Pharma, France) on the 22^nd^ day of the preceding cycle. Ovarian stimulation started after 14 days of downregulation after checking that the endometrial thickness was less than 4 mm. Final follicular maturation was induced by a single injection of 250 μg of choriogonadotropin alpha (Ovitrelle, Merck Serono Europe Limited, United Kingdom) when two or more leading follicles reached a mean diameter of 17 mm.

If the GnRH antagonist protocol was used, ovarian stimulation started on cycle Day 2. Daily GnRH antagonist cotreatment was added from cycle Day 6. Final maturation could be induced by a single injection of 250 μg of choriogonadotropin alpha (Ovitrelle, Merck Serono Europe Limited, United Kingdom) or by a dual trigger (250 μg of choriogonadotropin alpha plus 0.3 mg of Triptorelin) when two or more leading follicles reached a mean diameter of 17 mm.

Ovarian stimulation was performed using either r-FSH, r-FSH/r-LH or hMG. Dose adjustments were performed according to ovarian response, as monitored by transvaginal ultrasound during treatment. OPU was performed 36 h after the ovulation trigger. IVF or ICSI was performed according to normal clinical practice.

Luteal phase support {#sec010}
--------------------

All patients received a 10 mg three-times-daily dose of oral dydrogesterone (Duphaston, Mylan Medical, France) starting on the day of OPU \[[@pone.0220450.ref014],[@pone.0220450.ref015]\]. We systematically checked with the patients' compliance with this treatment on the day of ET. No additional treatment (neither hCG nor GnRH agonist bolus) was ever used during the luteal phase. Oral dydrogesterone administration continued from the day of OPU until the day of pregnancy testing or until the seventh gestational week (in the case of pregnancy).

Hormone analysis {#sec011}
----------------

On day 2--3 after OPU, immediately before ET, blood samples were collected for P~4~ and estradiol determination. We used an automated Cobas e411 instrument (Roche Diagnostics, Mannheim, Germany) and the same assays for all hormone measurements during the entire study. Samples were tested by an electrochemiluminescence immunoassay for Progesterone III (Cobas 07092539 190). The intra- and inter-assay variation coefficients for the P determinations were 3.3% and 5.2%, respectively, and sensitivity was 0.2 ng/ml.

Endpoints {#sec012}
---------

hCG serum level was measured 14 days after ET and considered positive if hCG \> 10 UI/ml. Clinical pregnancy was defined as the presence of a live fetus within an intrauterine gestational sac upon ultrasound examination at gestational weeks 6--7. Early pregnancy loss was defined by positive hCG testing at Day 14 and the absence of a live fetus within an intrauterine gestational sac upon ultrasound examination at gestational weeks 6--7. Thus, this definition includes patients with decreasing hCG after the first test, patients with no intrauterine gestational sac during the first ultrasound, patients with ectopic pregnancy and patients with a visible embryo without cardiac activity. Clinical pregnancy loss was defined as the loss of a viable intrauterine pregnancy between the first ultrasound up to and including gestational weeks 24 + 0. A live birth was defined as the delivery of a live infant after gestational week 24 + 0. Clinical gestational dating was performed using the day of OPU as gestational week 2 + 0 \[[@pone.0220450.ref011]\].

Statistical analysis {#sec013}
--------------------

Data are presented as percentages for categorical variables, as means and standard deviations for continuous parametric variables and as medians and ranges for continuous nonparametric variables.

First, a receiver operating characteristic (ROC) curve was used to evaluate the ability of early luteal P~4~ levels to predict live birth and to determine thresholds that could discriminate patients while maximizing sensitivity (Se) and specificity (Sp) with a good Youden index (*Se + Sp-- 1*). Three P~4~ groups were thus formed using the optimal thresholds found (\< 115 nmol/l, \[115--252\] nmol/l and \> 252 nmol/l). ANOVA and χ^2^ tests were used, respectively, to compare continuous and categorical characteristics among the three P~4~ groups.

Second, the multiple logistic regression model used by Thomsen et al. was applied to assess the differences in terms of reproductive outcomes among the aforementioned P~4~ groups \[[@pone.0220450.ref011]\]. The model included the independent variables maternal age, maternal BMI, final follicle count on the day of trigger (\>14 mm) and late follicular P~4~ level (\>4.77 nmol/l) to estimate positive hCG levels, clinical pregnancy and live birth. For estimates of early pregnancy loss, adjustments were made for maternal age, maternal BMI, smoking, final follicle count and peak estradiol level on the day of trigger.

Third, to compare our results to those of the Thomsen et al. study, we conducted a multiple logistic regression by retaining only patients who responded to the same inclusion criteria (age \< 41, BMI \< 35, and excluding the flare up protocols). We compared the same P~4~ groups (\< 60 nmol/l; \[60--100 nmol/l\]; \[100--400 nmol/l\]; \> 400 nmol/l) to determine the differences in terms of reproductive outcomes.

All statistical analyses were two-tailed, and results were considered significant when p-values \< 0.05 were obtained. These analyses were performed using IBM SPSS Statistics 20.0 (IBM Inc., New York, USA).

Results {#sec014}
=======

Study population and reproductive outcomes {#sec015}
------------------------------------------

During the selected time period, 242 women who were undergoing IVF treatment at our ART unit had a blood sample on the day of ET and were included in the study. Baseline characteristics of participants are provided in [Table 1](#pone.0220450.t001){ref-type="table"}, and cycle characteristics with crude reproductive outcomes are presented in [Table 2](#pone.0220450.t002){ref-type="table"}. The mean age of patients enrolled was 34.9 ± 4.7 years, and the mean BMI was 24.8 ± 5.3 kg/m^2^. After IVF treatment, 69 (28.5%) patients had a positive hCG level and 22 (9.1%) patients had early pregnancy loss, leaving 47 (19.4%) patients with clinical pregnancy. Overall, 43 (17.8%) patients gave birth to live children.

10.1371/journal.pone.0220450.t001

###### Baseline characteristics.

![](pone.0220450.t001){#pone.0220450.t001g}

  Progesterone (nmol/l)      N     All               \< 115            115--252          \> 252            P
  -------------------------- ----- ----------------- ----------------- ----------------- ----------------- -----------------------------------------------
  Number of patients, n            242               50                122               70                
  Maternal age (years)       242   34.9 ± 4.8        37.4 ± 3.9        34.5 ± 4.6        33.7 ± 5.0        \<0.01[\*\*](#t001fn003){ref-type="table-fn"}
  Maternal BMI (kg/m^2^)     242   24.8 ± 5.3        27.5 ± 6.8        23.8 ± 4.15       24.5 ± 5.2        \<0.01[\*\*](#t001fn003){ref-type="table-fn"}
  Maternal smoking (%)       242   21                20                25                14                0.235
  Basal FSH (IU)             236   6.8 (1.7--16.3)   7.5 (3.6--13.9)   7.2 (1.7--16.3)   6.2 (2.4--13.4)   0.001[\*\*](#t001fn003){ref-type="table-fn"}
  Basal LH (IU)              234   5.0 (0.1--35.0)   4.5 (1.6--17.0)   5.1 (1.4--35.0)   4.9 (0.1--23.0)   0.549
  Basal AMH (IU)             242   1.9 (0.1--17.0)   1.1 (0.1--11.5)   1.9 (0.1--17.0)   2.9 (0.5--9.8)    \<0.01[\*\*](#t001fn003){ref-type="table-fn"}
  Antral follicle count, n   217   13 (2--55)        11 (2--55)        13 (4--38)        16 (4--42)        \<0.01[\*\*](#t001fn003){ref-type="table-fn"}
  Primary diagnosis          242                                                                           
  Unexplained (%)                  23                16                33                10                \<0.01[\*\*](#t001fn003){ref-type="table-fn"}
  Tubal (%)                        27                32                25                27                0.608
  Endometriosis (%)                13                14                14                11                0.871
  PCO/PCOS (%)                     12                8                 7                 23                \<0.01[\*\*](#t001fn003){ref-type="table-fn"}
  Male (%)                         25                30                21                29                0.377

Descriptive data are presented as the mean ± SD for continuous parametric data and as the median (range) for continuous nonparametric data. Categorical data are presented as percentages (%).

SI conversion factor for P4: nmol/l = 3.18 ng/ml.

\*\*p\< 0.01

10.1371/journal.pone.0220450.t002

###### Descriptive data for controlled ovarian stimulation, oocytes, embryo transfer, and reproductive outcomes.

![](pone.0220450.t002){#pone.0220450.t002g}

  Progesterone (nmol/l)                              N     All                 \< 115              115--252            \> 252              P
  -------------------------------------------------- ----- ------------------- ------------------- ------------------- ------------------- ------------------------------------------------
  Number of patients, n (%)                                242                 50 (21%)            122 (50%)           70 (29%)            
  Protocol                                           242                                                                                   
  Antagonist (%)                                           64                  60                  60                  76                  0.066
  Long GnRH agonist (%)                                    28                  22                  33                  21                  0.449
  Flare up (%)                                             8                   18                  7                   3                   0.011[\*](#t002fn003){ref-type="table-fn"}
  Total FSH dose (IU)                                242   2925 (1000--7200)   3450 (1125--6750)   2850 (1125--7200)   2475 (1000--6750)   \<0.001[\*\*](#t002fn004){ref-type="table-fn"}
  Stim duration (days)                               242   10.5 ± 1.7          10.3 ± 1.9          10.4 ± 1.7          10.7 ± 1.6          0.399
  Final follicle count \>14 mm on trigger day        240   8 (2--24)           5 (2--17)           8 (3--16)           10 (2--24)          \<0.001[\*\*](#t002fn004){ref-type="table-fn"}
  Mode of triggering for final oocyte maturation     242                                                                                   0.353
  hCG (%)                                                  69                  62                  70                  75                  
  Dual trigger (%)                                         31                  38                  30                  25                  
  Number of mature oocytes retrieved (n)             242   8 (1--25)           4 (1--14)           8 (1--20)           12 (2--25)          \<0.001[\*\*](#t002fn004){ref-type="table-fn"}
  Number of fertilized oocytes (n)                   242   5 (1--19)           3 (1--8)            5 (1--17)           6 (1--19)           \<0.001[\*\*](#t002fn004){ref-type="table-fn"}
  Single embryo transfer (%)                         242   26                  40                  24                  21                  0.048[\*](#t002fn003){ref-type="table-fn"}
  Double embryo transfer (%)                         242   74                  60                  76                  79                  
  At least one top quality embryo for transfer (%)   242   25                  26                  26                  21                  0.741
  Positive hCG, n (%)                                242   69 (28.5%)          9 (18.0%)           33 (27.0%)          27 (38.6%)          0.043[\*](#t002fn003){ref-type="table-fn"}
  Early pregnancy loss, n (%)                        242   22/69 (31.9%)       5/9 (55.6%)         11/33 (33.3%)       6/27 (22.2%)        0.182
  Clinical pregnancy, n (%)                          242   47 (19.4%)          4 (8.0%)            22 (18,0%)          21 (30.0%)          0.009[\*\*](#t002fn004){ref-type="table-fn"}
  Live birth, n (%)                                  242   43 (17.8%)          3 (6.0%)            21 (17.2%)          19 (27.1%)          0.011[\*](#t002fn003){ref-type="table-fn"}

Descriptive data are presented as the mean ± SD for continuous parametric data and as the median (range) for continuous nonparametric data. Categorical data are presented as percentages (%).

SI conversion factor for P4: nmol/l = 3.18 ng/ml.

\*p\<0.05

\*\*p\<0.01

Threshold and P~4~ groups {#sec016}
-------------------------

The ROC curve for prediction of live birth based on early luteal P~4~ levels ([Fig 1](#pone.0220450.g001){ref-type="fig"}) allowed us to find two optimal thresholds and to identify three P~4~ groups: patients (n = 50) who had early luteal P~4~ \< 115 nmol/l had a significantly lower live birth rate (6.0%) than patients (n = 122) with P~4~ levels \[115--252 nmol/l\] (17.2%) and patients (n = 70) with P4 levels \> 252 nmol/l (27.1%; p = 0.011) ([Table 2](#pone.0220450.t002){ref-type="table"}). Similarly, the rates of positive hCG (p = 0.043) and clinical pregnancies (p = 0.009) significantly differed across the three groups. The rates of early pregnancy loss were 5/9 (55.6%), 11/33 (33.3%) and 6/27 (22.2%) respectively for the P~4~ groups \< 115 nmol/l, \[115--252 nmol/l\], \> 252 nmol/l. The low number of observations did not allow us to find any significant difference across groups for this reproductive outcome (p = 0.182).

![Receiving operative characteristic (ROC) curve for the prediction of live birth based on early luteal progesterone levels during IVF.\
Area under ROC curve = 0.599 (0.507--0.691), p = 0.042.](pone.0220450.g001){#pone.0220450.g001}

Multiple regression analysis {#sec017}
----------------------------

Due to missing data, the multiple regression analysis using the maternal age, the maternal BMI, the number of follicles \> 14 mm and the late follicular P~4~ levels \> 4.77 nmol/l was only conducted on 231 patients. The results of this analysis are presented in [Table 3](#pone.0220450.t003){ref-type="table"}. Patients who had early luteal P4 levels \< 115 nmol/l had the poorest chance of giving live birth (adjusted OR = 0.10 \[0.02--0.52\]) compared with patients with early luteal P~4~ \> 252 nmol/l. Patients with early luteal P~4~ \[115--252 nmol/l\] also had a significantly lower chance of giving live birth than patients with P~4~ \> 252 nmol/l (adjusted OR = 0.40 \[0.18--0.91\]). The same significative differences were obtained for the positive hCG and the clinical pregnancies but not for the early pregnancy losses ([Table 3](#pone.0220450.t003){ref-type="table"}).

10.1371/journal.pone.0220450.t003

###### Reproductive outcomes in the different luteal progesterone groups.

![](pone.0220450.t003){#pone.0220450.t003g}

                       OR for positive hCG   OR for clinical pregnancy                  OR for live birth   OR for early pregnancy loss                                                                                                                                                                                                                                                                             
  -------------------- --------------------- ------------------------------------------ ------------------- -------------------------------------------- -------- ------------------------------------------ -------- -------------------------------------------- -------- ------------------------------------------ -------- -------------------------------------------- ------- ---------------------- ------- ------------------------
  N                    69/242                242[\*](#t003fn001){ref-type="table-fn"}   63/231              231[\*\*](#t003fn002){ref-type="table-fn"}   47/242   242[\*](#t003fn001){ref-type="table-fn"}   43/231   231[\*\*](#t003fn002){ref-type="table-fn"}   43/242   242[\*](#t003fn001){ref-type="table-fn"}   39/231   231[\*\*](#t003fn002){ref-type="table-fn"}   22/69   69                     20/65   65
  P4 \< 115 nmol/l     9/50                  0.35 \[0.15--0.83\]                        8/48                0.26 \[0.09--0.76\]                          4/50     0.20 \[0.06--0.64\]                        3/48     0.13 \[0.03--0.53\]                          3/50     0.17 \[0.05--0.617\]                       2/48     0.10 \[0.01--0.52\]                          5/9     4.37 \[0.89--21.61\]   5/9     10.42 \[0.84--129.16\]
  P4 115--252 nmol/l   33/122                0.59 \[0.32--1.10\]                        30/117              0.47 \[0.24--0.99\]                          22/122   0.51 \[0.26--1.02\]                        20/117   0.36 \[0.16--0.80\]                          21/122   0.56 \[0.27--1.13\]                        19/117   0.40 \[0.18--0.91\]                          11/33   1.750 \[0.55--5.59\]   10/31   3.64 \[0.72--18.23\]
  P4 \> 252 nmol/l     27/70                 1                                          25/66               1                                            21/70    1                                          20/66    1                                            19/70    1                                          18/66    1                                            6/27    1                      5/25    1

\*In the crude OR estimates, all 242 patients with embryo transfer are included.

\*\*Due to missing data for the covariate late follicular phase in 7 patients, the final follicle count \> 14 mm on trigger day for 2 patients, and the BMI for 2 patients, the final adjusted regression model included 231 patients.

Discussion {#sec018}
==========

To our knowledge, our study is the first to study the effect of the early luteal phase during IVF with the use of oral dydrogesterone for the LPS. Lotus I, a large double-blinded RCT recently demonstrated the noninferiority of oral dydrogesterone compared with micronized vaginal progesterone for LPS in terms of pregnancy rates and tolerability \[[@pone.0220450.ref013]\]. Several other prospective studies have shown the effectiveness and safety of oral dydrogesterone for LPS during IVF or ICSI cycles and higher satisfaction rates for women compared with micronized vaginal progesterone \[[@pone.0220450.ref007],[@pone.0220450.ref017]--[@pone.0220450.ref021]\]. Thus, according to some authors, dydrogesterone may become the new standard for LPS during fresh ET IVF cycles \[[@pone.0220450.ref015]\].

Our results suggest a positive association between early luteal P~4~ levels and reproductive outcomes in IVF treatment with oral dydrogesterone for the luteal support. Therefore, these results are not only inconsistent with the conclusion of Thomsen *et al*. but the complete opposite \[[@pone.0220450.ref011]\]. After applying the same exclusion criteria as in the Thomsen *et al*. study (age \< 41, BMI \< 35, and excluding the flare up protocols), only 179 patients were divided into the same P~4~ groups \<60 nmol/l; \[60--100 nmol/l\]; \[100--400 nmol/l\]; and \> 400 nmol/l (respectively n = 5; n = 12; n = 154; n = 8). Our results are compared to those of the Thomsen et al. study in [Fig 2](#pone.0220450.g002){ref-type="fig"}. Although the low number of subjects in three of the four groups in this analysis did not allow us to find any significant differences among groups, the results of the two cohorts of patients are clearly inconsistent. The P~4~ group \[60--100 nmol/l\] that was associated with the best clinical pregnancy rate in the Thomsen *et al*. study had the poorest chance in our study. Similarly, the P~4~ group \> 400 nmol/l that was associated with the poorest live birth rate in the aforementioned study was associated with the best live birth rate in our study.

![Comparison of the reproductive outcomes of our retrospective cohort (in green, right section, 179 patients) with the Thomsen *et al*. prospective cohort (in blue, left section, 389 patients).](pone.0220450.g002){#pone.0220450.g002}

The most plausible hypothesis for these discrepancies is that dydrogesterone interferes with the progesterone secretion by the *corpus lutei*. Indeed, we measured P~4~ levels only and do not report the dydrogesterone levels, which would have required the use of an instrumental chromatographic method \[[@pone.0220450.ref016],[@pone.0220450.ref022]\]. Although the influence of dydrogesterone on the secretion of progesterone during the luteal phase has not been fully elucidated, its administration lowers the P~4~ levels \[[@pone.0220450.ref023]\]. Two studies have also shown the efficacy of dydrogesterone administration to prevent premature LH surges in the context of frozen-thawed ET, suggesting negative feedback on the pituitary gland \[[@pone.0220450.ref023],[@pone.0220450.ref024]\]. Although it is clearly impossible with the present study to estimate the respective weights of influence of exogenous dydrogesterone and endogenous progesterone on the outcomes of IVF treatment, our study clearly illustrates that the thresholds suggested by Thomsen et al. are not transposable when dydrogesterone is used for the LPS.

The present study has several limitations. The small sample size forced us to conduct the statistical analysis on early luteal P~4~ cut-off values that were determined in a data-dependent way. This method of analysis is known to bear the risk of finding an effect in the sample while no real difference exists in the population \[[@pone.0220450.ref012],[@pone.0220450.ref025]\]. Although we noticed the same trends when the data were analyzed in an objective way--i.e. percentile groups--due to sample size, we were unable to show significant differences using this analysis. Comparability of our P~4~ groups could also be criticized, as there are significant differences between groups. To overcome this issue, we chose to use the exact same variables as Thomsen *et al*. for the multiple regression analysis \[[@pone.0220450.ref011]\]. They used a Directed Acyclic Graph to identify a minimum set of covariates to adjust for in the statistical analysis. However, in the present study, the sample size was too small to show significant differences between groups by using a classical selection process for the multiple regression. Therefore, we cannot formally exclude a confusion bias. Overall, in addition to the retrospective nature of the study, the lack of statistical power does not allow us to present an irreproachable conclusion and further larger prospective cohort studies must be conducted. Another obvious limitation of the present study is the absence of early luteal phase dydrogesterone level measurements. This missing information prevents us from fully concluding on the pathophysiological mechanisms involved in the relationship between P~4~ levels and reproductive outcomes. Nevertheless, we successfully identified early luteal P~4~ thresholds that--if confirmed by prospective studies--may be used in clinical practice. Indeed, we determined that 21% of our patients who had P~4~ levels below 115 nmol/l had a dramatically poor live-birth rate (6.0%). If confirmed, this finding would encourage physicians to cancel the ET for these patients. The effect of increasing the supplementation is more intangible because the dydrogesterone might induce negative feedback over the progesterone secretion of the *corpus lutei* \[[@pone.0220450.ref023]\]. Furthermore, increasing progesterone or dydrogesterone supplementation does not proportionally increase the serum levels, and uterine progesterone levels do not correlate well with serum levels \[[@pone.0220450.ref026]--[@pone.0220450.ref029]\]. These pharmacokinetic data add to the uncertainty regarding strategies to increase the LPS in the case of low early luteal P~4~ levels.

Thus, our results should be interpreted with utmost precautions, and we only conclude that early luteal P~4~ levels and the reproductive outcomes in IVF with oral dydrogesterone for luteal support appear to be positively associated. The current state of knowledge on early luteal P~4~ monitoring is still too weak to allow for consideration of interventional studies or clinical applications. Further larger prospective cohort studies must be conducted to determine reliable thresholds that could be used to personalize LPS.
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